ERA-EDTA congress 2011: Late Breaking Clinical Trials II / Lowering LDL cholesterol does not significantly slow down CKD progression
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...